Does reduction in mycophenolic acid dose compromise efficacy regardless of tacrolimus exposure level? An analysis of prospective data from the Mycophenolic Renal Transplant (MORE) Registry

Consensus Report on Therapeutic Drug Monitoring of Mycophenolic Acid in Solid Organ Transplantation

(2010) D. R.J. Kuypers et al.   Clinical Journal of the American Society of Nephrology

Impact of gastrointestinal-related side effects on mycophenolate mofetil dosing and potential therapeutic strategies

(2010) Suphamai Bunnapradist et al.   CLINICAL TRANSPLANTATION

Calcineurin Inhibitor Sparing With Mycophenolate in Kidney Transplantation: A Systematic Review and Meta-Analysis

(2010) Jason Moore et al.   TRANSPLANTATION

Mycophenolate Mofetil Versus Enteric-Coated Mycophenolate Sodium: A Large, Single-Center Comparison of Dose Adjustments and Outcomes in Kidney Transplant Recipients

(2010) Hans W. Sollinger et al.   TRANSPLANTATION

Calcineurin Inhibitor Minimization in the Symphony Study: Observational Results 3 Years after Transplantation

(2009) H. Ekberg et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Fixed- or Controlled-Dose Mycophenolate Mofetil with Standard- or Reduced-Dose Calcineurin Inhibitors: The Opticept Trial

(2009) R. S. Gaston et al.   AMERICAN JOURNAL OF TRANSPLANTATION

EC-MPS permits lower gastrointestinal symptom burden despite higher MPA exposure in patients with severe MMF-related gastrointestinal side-effects

(2009) Massimo Sabbatini et al.   FUNDAMENTAL & CLINICAL PHARMACOLOGY

Effect of conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium on maximum tolerated dose and gastrointestinal symptoms following kidney transplantation

(2009) Magdi Shehata et al.   TRANSPLANT INTERNATIONAL

Effect on Kidney Graft Survival of Reducing or Discontinuing Maintenance Immunosuppression After the First Year Posttransplant

(2009) Gerhard Opelz et al.   TRANSPLANTATION

Comparing Outcomes Associated With Dose Manipulations of Enteric-Coated Mycophenolate Sodium Versus Mycophenolate Mofetil in Renal Transplant Recipients

(2009) Matthew Cooper et al.   TRANSPLANTATION

Evaluation of Tolerability and Ability to Increase Immunosuppression in Renal Transplant Patients Converted From Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium

(2009) J.-F. Bilodeau et al.   TRANSPLANTATION PROCEEDINGS

Mycophenolate Mofetil Dose Reduction in Renal Transplant Recipients: A 5-Year Follow-up Study

(2009) H.T. Khosroshahi et al.   TRANSPLANTATION PROCEEDINGS

Inadequate Mycophenolic Acid Exposure and Acute Rejection in Kidney Transplantation

(2009) A.I. Sánchez-Fructuoso et al.   TRANSPLANTATION PROCEEDINGS

Economic Impact and Long-Term Graft Outcomes of Mycophenolate Mofetil Dosage Modifications Following Gastrointestinal Complications in Renal Transplant Recipients

(2008) Gerardo Machnicki et al.   PHARMACOECONOMICS

The Effect of Mycophenolate Mofetil and Azathioprine Dose on Renal Allograft Outcome in the United Kingdom

(2008) Sapna Shah et al.   TRANSPLANTATION

Comparing Mycophenolate Mofetil Regimens for de Novo Renal Transplant Recipients: The Fixed-Dose Concentration-Controlled Trial

(2008) Teun van Gelder et al.   TRANSPLANTATION